Cargando…
P512: A PHASE 1B/2 STUDY OF TP-0903 AND DECITABINE TARGETING MUTANT TP53 AND/OR COMPLEX KARYOTYPE IN PATIENTS WITH UNTREATED ACUTE MYELOID LEUKEMIA (AML) ≥ AGE 60 YEARS: FINAL RESULTS
Autores principales: | Mims, Alice, Huang, Ying, Eisenmann, Eric, Orwick, Shelley, Buelow, Daelynn, Swords, Ronan, Zeidner, Joshua, Foster, Matthew, L. Lin, Tara, Baer, Maria, Madanat, Yazan, Kovacsovics, Tibor, Redner, Robert, Al-Mansour, Zeina, Stefanos, Mona, Martycz, Molly, Druggan, Franchesca, Chen, Timothy, Yocum, Ashley, Borate, Uma, Druker, Brian, Burd, Amy, Levine, Ross, Baker, Sharyn, C. Byrd, John |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428724/ http://dx.doi.org/10.1097/01.HS9.0000968956.29381.19 |
Ejemplares similares
-
TP-0903 Is Active in Preclinical Models of Acute Myeloid Leukemia with TP53 Mutation/Deletion
por: Eisenmann, Eric D., et al.
Publicado: (2022) -
TP-0903 is active in models of drug-resistant acute myeloid leukemia
por: Jeon, Jae Yoon, et al.
Publicado: (2020) -
Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates
por: Saliba, Antoine N., et al.
Publicado: (2022) -
BMX kinase mediates gilteritinib resistance in FLT3-mutated AML through microenvironmental factors
por: Buelow, Daelynn R., et al.
Publicado: (2022) -
Assessment of Tp–e interval, Tp–e/QT, and Tp-e/QTc ratios in patients with acromegaly
por: ÇELİK, İbrahim Etem, et al.
Publicado: (2022)